Epidemiologic Registry for the Description of Antiemetic Strategies Under Real-life Conditions.

iOMEDICO AG1 site in 1 country1,035 target enrollmentOctober 2008

ConditionsAntiemetic Therapy

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Antiemetic Therapy
Sponsor: iOMEDICO AG
Enrollment: 1035
Locations: 1
Primary Endpoint: Efficacy of anti-emetic therapies dependent on the rate "complete and major control" of nausea and emesis in moderately and highly emetogenic chemotherapy regimens.
Status: Completed
Last Updated: 11 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this registry is to record information on reality of anti-emetic therapies of cancer-patients in Germany. The outcome of this study is the efficacy of anti-emetic therapies dependent on the rate "complete and major control" of nausea and emesis in moderately and highly emetogenic chemotherapies, consisting of platin-derivates (cisplatin, carboplatin and oxaliplatin), anthracyclines and/or cyclophosphamid.

Registry

clinicaltrials.gov

Start Date

October 2008

End Date

August 2009

Last Updated

11 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

iOMEDICO AG

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Moderately or highly emetogenic chemotherapy consisting of platin-derivates (cisplatin, carboplatin and oxaliplatin), anthracyclines and/or cyclophosphamid.
•start with the 1st cycle of the regimen (chemo naive patients). Inclusion of pretreated patients is also possible, if the last treatment cycle of a previous chemotherapy was given \>= 24 months ago.
•Compliance with registry procedures
•Age \>= 18 years
•WHO Performance Status of 0 or 1 (Karnofsky-Index \>= 70%)
•Life expectancy of at least 12 weeks
•Signed and dated informed consent before the start of the registry

Exclusion Criteria

•Mentally incapable or incompliant patients
•Last chemotherapy \<= 24 months (if pretreated)
•Known hypersensitivity to antiemetic medication
•unability of the patient to be treated with oral medication
•pregnancy or lactation period

Outcomes

Primary Outcomes

Efficacy of anti-emetic therapies dependent on the rate "complete and major control" of nausea and emesis in moderately and highly emetogenic chemotherapy regimens.

Time Frame: 4 chemotherapy applications per patient